Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3885651 Target Snapshot

Urease subunit alpha/Urease subunit beta · PROTEIN COMPLEX · Helicobacter pylori (strain ATCC 700392 / 26695) (Campylobacterpylori)

372Compounds
67Assays
4Approved Drugs
591.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P69996. Use UniProt P69996 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P69996 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Urease subunit alpha/Urease subunit beta as ChEMBL target CHEMBL3885651, mapped to UniProt P69996. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Urease subunit alpha/Urease subunit beta
PROTEIN COMPLEX · Helicobacter pylori (strain ATCC 700392 / 26695) (Campylobacterpylori)
As of 2026-09-14
ChEMBL target ID
CHEMBL3885651
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P69996
Urease subunit beta
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Urease subunit alpha/Urease subunit beta is the right protein anchor across sources, using UniProt P69996 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelUrease subunit beta
UniProt AccessionP69996
Component TypeProtein
Sequence Length569 aa

Urease subunit beta

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Urease subunit alpha/Urease subunit beta, mapped to UniProt P69996. ChEMBL maps the protein component as Urease subunit beta. Sequence length is 569 aa.

Mapped IDP69996
Review nameUrease subunit alpha/Urease subunit beta
OrganismHelicobacter pylori (strain ATCC 700392 / 26695) (Campylobacterpylori)
Clinical Profile

Clinical Phase Distribution

4
Approved
4
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC50561.0
KI29.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5209436 9.47 Kd 0.34 Preclinical
CHEMBL2425469 7.85 Ki 14.0 Preclinical
CHEMBL4172924 7.75 IC50 18.0 Preclinical
CHEMBL4167553 7.37 IC50 43.0 Preclinical
CHEMBL4251246 7.37 Ki 43.0 Preclinical
CHEMBL2425478 7.35 Ki 45.0 Preclinical
CHEMBL4162915 7.26 IC50 55.0 Preclinical
CHEMBL4243350 7.21 IC50 61.0 Preclinical
CHEMBL5209436 7.19 Ki 65.0 Preclinical
CHEMBL2425469 7.08 IC50 83.0 Preclinical
Distribution

pChEMBL Value Distribution

56
5.0
34
5.5
21
6.0
11
6.5
9
7.0
3
7.5
0
8.0
0
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

RABEPRAZOLE
CHEMBL1219
Approved 1999
Assay Landscape

Assay Landscape

67
Total Assays
322
Tested Compounds
1
Assay Types
Binding — 67 assays, 322 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 37 180 5.2
assay format 30 142 4.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine